Similarly, for validation, the ‘IFN/EMT score’ was further shown to be associated with clinical benefits in a variety of advanced disease types (for example, metastatic urothelial cancer, melanoma, gastric cancer and nonsmall cell lung cancer) in patients who received anti-PD-(L)1 treatment (Extended Data Fig. 4d). This evidence concerns the gene IFNA1 and melanoma.